BioSpace News Archive

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced that two oral and 13 poster presentations about its Alzheimer’s Disease (AD), dementia pipeline will be presented at the 2019 Alzheimer’s Association International Conference (AAIC), July 14-18, in Los Angeles.

Elicio Therapeutics, today announced that studies of its Amphiphile platform in combination with CAR-T therapy (AMP-CAR-T) have shown that activation of CAR-T cells in the lymphatic system gives massive CAR-T cell expansion, and significant functional improvements including enhanced CAR-T cell infiltration of solid tumors, increased anti-tumor cytolytic potential, and improved cytokine response.

Female leaders now represent 50 percent of the Blue Cross executive leadership team

Researchers presented eight abstracts at 2019 ADSA showing benefits of feeding OmniGen™, Animate® and Cellerate Yeast Solutions®

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, July 25, 2019, to discuss its financial and operating results for the second quarter of 2019.

Ocular Therapeutix™, Inc. announced that the Company entered into an employment agreement that provided for the grant of an inducement award outside the Company’s 2014 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635.

Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, is proud to announce Co-founder Chad A. Mirkin has been awarded the $250,000 Kabiller Prize in Nanoscience and Nanomedicine for discovering and developing spherical nucleic acids (SNAs).

Capital BlueCross announced the launch of “My Cap BlueCross,” a voice enabled healthcare educational skill for Amazon Alexa or Google Home devices.

Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, and Ono Pharmaceutical Co., Ltd. today announced an exclusive license agreement for the development, manufacture and commercialization of 5F9, Forty Seven’s monoclonal antibody against CD47.

Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.